Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/antibiotics9050255 http://scihub22266oqcxt.onion/10.3390/antibiotics9050255 32429032!7277631!32429032     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Antibiotics+(Basel) 2020 ; 9 (5): ä Nephropedia Template TP {{tp|p=32429032|t=2020. Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist |pdf=|usr=}}{{32429032}} gab.com Text Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist JO: Antibiotics (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=32429032 #FOAvip Recently, the research community has had a real-world look at reasons for improving vaccine responses to emerging RNA viruses. Here, a vaccine non-specialist suggests how this might be done. I propose two alternative options and compare the primary alternative option with current practice. The basis of comparison is feasibility in achieving what we need: a safe, mass-produced, emerging virus-targeted vaccine on 2-4 week notice. The primary option is the following. (1) Start with a platform based on live viruses that infect bacteria, but not humans (bacteriophages, or phages). (2) Isolate phages (to be called pathogen homologs) that resemble and provide antigenic context for membrane-covered, pathogenic RNA viruses; coronavirus-phage homologs will probably be found if the search is correctly done. (3) Upon isolating a viral pathogen, evolve its phage homolog to bind antibodies neutralizing for the viral pathogen. Vaccinate with the evolved phage homolog by generating a local, non-hazardous infection with the phage host and then curing the infection by propagating the phage in the artificially infecting bacterial host. I discuss how this alternative option has the potential to provide what is needed after appropriate platforms are built. Twit Text FOAVip Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist ????Antibiotics (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=32429032 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32429032 #FOAvip English Wikipedia <ref>{{Cite pmid|32429032}}</ref> Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist #MMPMID32429032 Serwer P Antibiotics (Basel) 2020[May]; 9 (5): ä PMID32429032show ga Recently, the research community has had a real-world look at reasons for improving vaccine responses to emerging RNA viruses. Here, a vaccine non-specialist suggests how this might be done. I propose two alternative options and compare the primary alternative option with current practice. The basis of comparison is feasibility in achieving what we need: a safe, mass-produced, emerging virus-targeted vaccine on 2-4 week notice. The primary option is the following. (1) Start with a platform based on live viruses that infect bacteria, but not humans (bacteriophages, or phages). (2) Isolate phages (to be called pathogen homologs) that resemble and provide antigenic context for membrane-covered, pathogenic RNA viruses; coronavirus-phage homologs will probably be found if the search is correctly done. (3) Upon isolating a viral pathogen, evolve its phage homolog to bind antibodies neutralizing for the viral pathogen. Vaccinate with the evolved phage homolog by generating a local, non-hazardous infection with the phage host and then curing the infection by propagating the phage in the artificially infecting bacterial host. I discuss how this alternative option has the potential to provide what is needed after appropriate platforms are built. äOptimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist (epmc).pdf DeepDyve Pubget Overpricing